Molecular pathology, an emerging discipline within pathology, is focused in the study and diagnosis of disease through the examination of molecules within organs, tissues or bodily fluids. It encompasses the development of molecular and genetic approaches to the diagnosis and classification of human tumors, the design and validation of predictive biomarkers for treatment response and disease progression, the susceptibility of individuals of different genetic constitution to develop cancer and the environmental and lifestyle factors implicated in carcinogenesis.
As a result, the practice of molecular pathology is constantly changing. New genes discovered, pharmacologic targets identified, patient responses based on inherited and/or acquired genetic changes. We at Delta MDx continually strive to provide state-of-the art testing solutions for your patient needs. Committed to both assay development and education, we will work to not only improve our testing repertoire, but will commit to early implementation of novel assays, designed for patient care.
Research efforts at Delta MDx include primarily translational projects, destined for clinical implementation. Current work involves the discovery of BRAF mutations in cases of thyroid carcinoma, FISH assays for the differential diagnosis of melanoma, and EGFR mutations in non-small cell lung cancer to predict therapeutic response to EGFR inhibitors. Research priorities and assay development is a team effort by all of the Delta MDx staff.